Home › Kanser sa Suso › Texas › Fort Worth
Pag-aaral pangklinika para sa Kanser sa Suso sa Fort Worth, TX
Isang pag-aaral para sa Kanser sa Suso ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Fort Worth. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
A Study of PHST001 in Advanced Solid Tumors
Nagre-recruitPhase 1
- START Center for Cancer Research - Texas, Fort Worth
IKS014 in Advanced Solid Tumors That Express HER2
Nagre-recruitPhase 1
- START Dallas - Fort Worth, Fort Worth
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Nagre-recruitPhase 3
- JPS Health Network ( Site 0067), Fort Worth
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Nagre-recruitPhase 3
- The Center for Cancer and Blood Disorders ( Site 0041), Fort Worth
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Nagre-recruitPhase 3
- JPS Oncology and Infusion Center ( Site 0083), Fort Worth
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
Nagre-recruitPhase 3
- JPS Health Network, Fort Worth
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Nagre-recruitPhase 3
- JPS Health Network - Trinity Springs Pavilion, Fort Worth
- OneR The Center For Cancer And Blood Disorders (Texas Cancer Care), Fort Worth
- UT Southwestern Moncrief Cancer Institute, Fort Worth
- at 2 pa
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Nagre-recruitPhase 1
- Start - Dfw, Fort Worth
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
Nagre-recruitPhase 3
- Research Site, Fort Worth
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Nagre-recruitPhase 3
- JPS Health Network, Fort Worth
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Nagre-recruitPhase 1/2
- USOR Texas Oncology, Fort Worth
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Nagre-recruitPhase 3
- UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth
Pag-aaral para sa Kanser sa Suso sa ibang lungsod
- New York City, NY136 pag-aaral
- Houston, TX126 pag-aaral
- Boston, MA112 pag-aaral
- Nashville, TN81 pag-aaral
- Los Angeles, CA73 pag-aaral
- Edison, NJ68 pag-aaral
- St. Louis, MO64 pag-aaral
- Queens, NY64 pag-aaral
- Durham, NC64 pag-aaral
- Chicago, IL59 pag-aaral
- Philadelphia, PA56 pag-aaral
- Dallas, TX55 pag-aaral
Iba pang pag-aaral sa Fort Worth
- Non-Small Cell Lung Cancer18 pag-aaral
- Kanser sa Ovary17 pag-aaral
- Kanser ng Endometrium12 pag-aaral
- Kanser (lahat ng uri)9 pag-aaral
- Kanser sa Prostate9 pag-aaral
- Triple-Negative Breast Cancer7 pag-aaral
- Degenerasyon ng Macula7 pag-aaral
- Ulcerative Colitis7 pag-aaral
- Kanser sa Bato (Renal Cell Carcinoma)7 pag-aaral
- Pagkabigo ng Puso7 pag-aaral
- Metastatic Cancer7 pag-aaral
- Colorectal Cancer7 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.